Home Investor Relations

Press Release

Q2FY24 Financial Results
November 06, 2023 - Marksans Pharma Limited's WOS Relonchem Limited, receives marketing authorisation for Cyanocobalamin 50mg film coated tablets
November 03, 2023 - Marksans Pharma Limited's WOS Time-Cap Laboratories, Inc, receives Establishment Inspection Report from US FDA
November 01, 2023 - Marksans Pharma Limited undergoes successful inspection from German Health Authorities
October 03, 2023-Marksans Pharma Limited receives US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)
Press Release dated 22nd August, 2023 - Marksans Pharma receives USFDA approval for Guaifenesin
Extended-Release Tablets (OTC)
Press Release – Q1FY24 Financial Results
Press Release August 2023
Press Release July 2023
Press Release - Q4FY23 and FY23 Financial Results
Press Release dated 19th April, 2023 - Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India.
Press Release dated 10th March, 2023 - Marksans Pharma Limited announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg.
Press Release - Q3FY23
Press Release dated 23rd January, 2023 - Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
Press Release dated 20th January, 2023 - Marksans Pharma raises Rs. 372.40 crores in equity via conversion of warrants issued to OrbiMed and the Promoter
Press Release - Q2FY23
Press Release dated 11th October, 2022 - Marksans acquires capacity from Tevapharm India
Press release dated 13th August, 2022 – Q1FY23 Financial Results
US FDA approval for Pregabalin Capsules, 25 mg, 50 mg,75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg ANDA
Press Release dated 21.06.2022
Marksans Pharma signs agreement to acquire 100% stake in Dubai-based Access Healthcare for
Medical Products L.L.C
UK MHRA approval for Bells Healthcare All in One Oral Solution
US FDA final approval for Cetirizine Hydrochloride Tablets 5mg and 10mg
UK MHRA approval for Loperamide 2mg Hard Capsules
News Release November 2021
USFDA approval for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC)
News Release August 2021
News Release May 2021
News Release September 2020
Metformin Hydrochloride Extended Release Tablets, USP 500 mg & 750 mg
News Release June 2020
Clarification on news circulating through WhatsApp
Metformin Extended Release Tablets 500 mg
News Release March 2020
Metformin Extended Release Tablets 500 mg & 750 mg
News Release December 2019
News Release September 2019
News Release June 2019
Receipt of Establishment Inspection Report (EIR) from the US FDA
Performance Highlight – Consolidated Q4 2018-19
US FDA Audit Update
Performance Highlight - Consolidated Q3 2018-19
Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine
5mg / 5ml Oral Solution
Performance Highlight – Consolidated for H1 2018-19
Performance Highlight – Consolidated Q1 2018-19
Transfer of Shares in dematerialised form only
Performance Highlight – Consolidated Q4 2017-18
Performance Highlight – Consolidated Q3 2017-18
Performance Highlight - Consolidated for H1 2017-18
Performance Highlight - Consolidated Q1 2017-18
Receipt of Establishment Inspection Report
Performance Highlights - Consolidated
Marksans Pharma Limited - US FDA
Marksans Pharma Limited Announcement
Performance Highlights - Consolidated
Performance Highlights - Consolidated
Performance Highlights - Consolidated
Performance Highlights - Consolidated
Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended Release
News Release March 2016
News Release February 2016
News Release January 2016
News Release November 2015
News Release August 2015
News Release June 2015
News Release May 2015
News Release February 2015
News Release September 2014
Proceedings of 22nd AGM
Report of the Scrutinizer
Addendum to Notice of 22nd Annual General Meeting
News Release June 14